Group by Gene: PARP Inhibitors Tyrosine Kinase Inhibitors BCL Inhibitors Chemotherapy Other Serine-Threonine Kinase Inhibitors CD Protein Inhibitors Immune Checkpoint Inhibitors Immunotherapy DNA Threonine-Tyrosine Kinase Inhibitors Hormone Therapy | bevacizumab-adcd | Aybintio (bevacizumab biosimilar) | VEGF-A inhibitor bevacizumab-awwb | bevacizumab | bevacizumab-tnjn | bevacizumab-maly | VEGF-A inhibitor, PARP inhibitor bevacizumab + olaparib | bevacizumab + niraparib | niraparib | PARP inhibitor rucaparib | olaparib | pamiparib | anastrozole | Aromatase inhibitor exemestane | letrozole | Topoisomerase I inhibitor irinotecan | topotecan | Alkylating agent melphalan | cyclophosphamide | Topoisomerase II inhibitor pegylated liposomal doxorubicin | doxorubicin hydrochloride | DNA synthesis inhibitor cisplatin | cisplatin + gemcitabine | Tubulin polymerization promoter, Bcl2 inhibitor carboplatin + paclitaxel | paclitaxel | Tubulin polymerization promoter, Bcl2 inhibitor, Tubulin inhibitor carboplatin + micellar paclitaxel | Topoisomerase II inhibitor, DNA inhibitor etoposide oral | MEK inhibitor trametinib | Selective estrogen receptor degrader fulvestrant | DNA synthesis inhibitor, Topoisomerase I inhibitor cisplatin + irinotecan | Bcl2 inhibitor, Tubulin inhibitor albumin-bound paclitaxel | Multi-tyrosine kinase inhibitor pazopanib | Tubulin polymerization inhibitor vinorelbine tartrate | DNA synthesis inhibitor, DNA cross linking agent oxaliplatin | Bifunctional alkylating agent ifosfamide | Thymidylate synthase inhibitor capecitabine | Tubulin polymerization promoter, DNA synthesis inhibitor carboplatin + gemcitabine | Bifunctional alkylating agent, DNA synthesis inhibitor cisplatin + ifosfamide | Bifunctional alkylating agent, Tubulin polymerization promoter carboplatin + ifosfamide | Tubulin polymerization promoter carboplatin | Estrogen receptor antagonist tamoxifen | GnRH agonist leuprolide acetate | Topoisomerase II inhibitor, Tubulin polymerization promoter carboplatin + pegylated liposomal doxorubicin | TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor larotrectinib | PD1 inhibitor pembrolizumab | VEGFR inhibitor, DLL4 inhibitor OMP-305B83 | PARP1 inhibitor BSI 201 | RET inhibitor selpercatinib | EP | Chemotherapy VAC | BEP | CAPOX | VEGF-A inhibitor, Folate receptor 1-targeted antibody-drug conjugate, Microtubule inhibitor bevacizumab + mirvetuximab soravtansine-gynx | THF dehydrogenase inhibitor, Thymidylate synthase inhibitor pemetrexed | Microtubule stabilizer, Tubulin polymerization promoter carboplatin + docetaxel | DNA synthesis inhibitor, DNA cross linking agent, Thymidylate synthase inhibitor 5-fluorouracil + oxaliplatin | Tubulin polymerization promoter, DNA synthesis inhibitor, Bcl2 inhibitor cisplatin + paclitaxel | Bifunctional alkylating agent, Tubulin polymerization promoter, Bcl2 inhibitor paclitaxel + ifosfamide | pan-RAF inhibitor, Multi-tyrosine kinase inhibitor sorafenib | TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, TrkA receptor inhibitor, ALK inhibitor, JAK2 inhibitor, TNK2 inhibitor entrectinib | Folate receptor 1-targeted antibody-drug conjugate, Microtubule inhibitor STRO-002 | mirvetuximab soravtansine-gynx | VEGF-A inhibitor, Microtubule inhibitor bevacizumab + ixabepilone |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No biomarker | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FOLR1 expression | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FOLR1 positive | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
HRD + BRCA1 mutation | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
HRD + BRCA2 mutation | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BRCA2 mutation | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BRCA1 mutation | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NTRK3 fusion | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RET fusion | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
HRD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PD-L1 expression | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TMB-H | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RAD51C mutation | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
MSI-H/dMMR | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NTRK2 fusion | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NTRK1 fusion | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TUBB3 expression |